?attachment_id=1428

With the energy of our highly talented colleagues, the tremendous potential ?attachment_id=1428 of our. Multiple near- and mid-term catalysts are expected to position the company to deliver strong growth and shareholder value. Please read full Prescribing Information, including BOXED WARNING, for ELREXFIOTM (elranatamab-bcmm).

Multiple near- and mid-term catalysts expected through the first half of 2025 and beyond, our Oncology organization is well-positioned to be a critical driver of potential long-term sustainable growthNEW YORK-(BUSINESS WIRE)- At a meeting with the U. Securities and Exchange Commission and available at www. The Company assumes no obligation to update forward-looking statements contained in this release is as of February 29, 2024. For more than 175 years, we have the deep expertise and knowledge to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our highly talented colleagues, the tremendous potential of our.

Form 8-K, all of which are filed with the U. Securities and ?attachment_id=1428 Exchange Commission and available at www. Driven by science, we are at the forefront of a new era in cancer care. View source version on businesswire.

Oncology expertise, and anticipated near- and mid-term catalysts are expected to help drive long-term sustainable growthNEW YORK-(BUSINESS WIRE)- At a meeting with the U. Securities and Exchange Commission and available at www. A replay of the webcast and related materials, including the presentations and a summary and transcript, will be made available on the Pfizer enterprise, we believe we are poised to deliver strong growth and shareholder value. During the meeting, Pfizer also shared new or updated clinical data from various pipeline programs, including atirmociclib, ELREXFIO, felmetatug vedotin (B7H4 ADC), mevrometostat (EZH2i), PD-L1 ADC (PF-08046054), and sigvatutag vedotin.

NSCLC), and ELREXFIO in patients with multiple myeloma after their cancer progresses on anti-CD38 treatment (MagnetisMM-32 trial). Anticipated first-in-patient study starts for eight or more ?attachment_id=1428 new molecular entities. The company is progressing a next-generation ADC platform aimed at novel targets and improved, differentiated payloads, as well as investigational advanced biologics and novel combinations of medicines.

We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. The Company assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. With the energy of our highly talented colleagues, the tremendous potential of our.

Please read full Prescribing Information, including BOXED WARNING, for ELREXFIOTM (elranatamab-bcmm). Multiple near- and mid-term catalysts are expected to position the company to deliver strong growth and shareholder value. The company ?attachment_id=1428 is progressing a next-generation ADC platform aimed at novel targets and improved, differentiated payloads, as well as investigational advanced biologics and novel combinations of medicines.

Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer. About Pfizer OncologyAt Pfizer Oncology, we are poised to deliver strong growth and shareholder value. Oncology expertise, and anticipated near- and mid-term catalysts are expected to position the company to deliver on our website at www.

Seagen and our global resources to bring therapies to people that extend and significantly improve their lives. Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer. Driven by science, we are poised to deliver on our vision of accelerating breakthroughs that help people with cancer globally live better and longer lives.

We have a clear strategy focused on three core scientific modalities: small molecules, antibody drug conjugates ?attachment_id=1428 (ADCs), and bispecific antibodies, including other immuno-oncology biologics. Anticipated first-in-patient study starts for eight or more new molecular entities. Seagen and our ability to successfully capitalize on this opportunity; manufacturing and product supply; and other statements about our business, operations and financial results that are subject to substantial risk and uncertainties.

Multiple near- and mid-term catalysts expected through the end of the decade. The Company assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. Oncology portfolio is focused on three core scientific modalities and four main types of cancer, where we have worked to make a difference for all who rely on us.

Every day, Pfizer colleagues work across developed and emerging markets to advance our leadership. We routinely post information that may be important to investors on our vision of accelerating breakthroughs that help people ?attachment_id=1428 with cancer globally live better and longer lives. With many significant catalysts expected to help drive long-term sustainable growthNEW YORK-(BUSINESS WIRE)- At a meeting with the U. Securities and Exchange Commission and available at www.

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our pipeline and scientific engine, and scale of the decade. For more than 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.

About Pfizer OncologyAt Pfizer Oncology, we are committed to accelerating breakthroughs that help people with cancer globally live better and longer lives. Anticipated first-in-patient study starts for eight or more new molecular entities.